The efficacy of co-administration of topical niosomal dapsone gel and intralesional injection of glucantime in cutaneous leishmaniasis in comparison with cryotherapy plus intralesional injection of glucantime

Journal of Kerman University of Medical Sciences

Volumn 22, Issue 2, 2015, Pages 117-132

  Fekri, Alireza ^a   Rahnama, Zahra ^a   Khalili, Maryam ^b   Dookhani, Abbas Pardakhti ^a   Khazaeli, Payam ^a   Beigi, Kambiz Bahaadin ^c  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dapsone; Leishmaniasis; Niosomal

Indexed keywords

DAPSONE; MEGLUMINE ANTIMONATE; NIOSOME;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CRYOTHERAPY; DATA ANALYSIS; FEMALE; FEWER; HUMAN; LIMB DISEASE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; TREATMENT RESPONSE; ULCERATIVE LESION;

EID: 84925940252     PISSN: 10239510     EISSN: 20082843     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Reithinger R, Mohebali M, Boucher B, et al. unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3:e162.
2. Desjeux P. the increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95(3): 239-43.
3. Jeronimo SB, Sousa A, Pearson RD. Leishmaniasis species. In:Mandell GL, Bennett JE, Dolin R. Principles and Practice of infections Diseases. 6th ed., Philadelphia, Churchill livingston 2005; PP 3145-65.
4. Dowlati Y. Cutaneus leishmaniasis: clinical aspect. Clin Dermatol 1996;14(5):425-31.
5. Mohajery M, Bolur saz M, Shamsian S A A, [A survey on the prevalence of cutaneous leishmaniasis in the students of Mashhad district. Journal of Mashhad faculty of medicine 2001; 44(72): 54-60 [In Persian].
6. Markle W.H, Makhoul K. Cutaneous leishmaniasis: Recognition and treatment. Am Fam Phisician 2004; 69(6):1455-60.
7. Al-Jaser M, el-Yazigi A, Kojan M, croft SL. Skin uptake, distribution and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob Agents cehmother 1995; 39(2): 516-9.
8. Azizi f, Hatam H, Janghorbani M. Epidemiology and control of common disorders in Iran. Tehran, Khosravi Pub, 2003; PP 524-32 [In Persian].
9. Athari A, Jalalloo N. Epidomiology of five year of cutaneuse Leishmanaiasis in Iran (2001-2005), Isfahan faculty of medicine journal 2006; 24: 8-13 [In Persian].
10. ShamsiMeimandi S, Zandi S, Dabiri SH. Efficacy of topical 5% imiquimod with cryotherapy versus intralesional meglumine antimoniate in treatment of anthroponotic cutaneous leishmaniasis. Iran Journal of Dermatology 2001; 14: 42-7.
11. Al-Jaser MH. Treatment trends of cutaneous leishmaniasis in Saudi Arabia. Saudi Med J 2005; 26(8): 1220-4.
12. Vardy D, Barenholz Y, Cohen R Zvulunov A, Biton A, Klaus S, et al. Topical amphotericin B for cutaneous leishmaniasis. Arch Dermatol 1999; 135(7):856-7.
13. Akilov OE, Kosaka S O, Riordan K, Hasan T. Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is direct and mediated through the killing of host cells. Exp Dermatol 2007; 16(8):651-60.
14. Dogra J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991;85(2):212-3.
15. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis, Int J Dermatol 2003; 41(8): 521-4.
16. Magill AJ. Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am 2005; 19(1): 241-66.
17. Dogra J, Lal BB, Misra SN Dapson in the treatment of cutaneous leishmaniasis. Int J Dermatol 1986; 25(6):398-400.
18. Al-Mutairi N., Alshiltawy M., El Khalawany M., Joshi A., Eassa B. I., Manchanda Y., et al. Tropical medicine rounds: Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination. Int J Dermatol 2009; 48(8): 862–9.
19. Zhu Y.I, Stiller M.J. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001; 45(3): 420-34.
20. Raimer S, Maloney JM, Bourcier M, Wilson D, Papp K, Siegfried E, et al. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Cutis 2008;81(2):171-8.
21. Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel 5%, for the treatment of acne vulgaris. J Am Acad Dermatol 2007; 56(3):439.e1-10.
22. Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drug Dermatol 2007; 6(10):981-7.
23. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate(Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43(4): 281–3.
24. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57(2): 335. e1-e29.
25. Munir A, Janjua SA, Hussain I. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerol Croat 2008;16(2):60-4.
26. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19(1):111-26.
27. Faghihi G, Tavakoli-kia, R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 2003; 28(1): 13-6.
28. Shazad B, Abbaszadeh B, Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. Major. Eur J Dermatol 2005; 15(2): 85-7.
29. Alavi-Naini R, Fazaeli A, O’Dempsey T. Topical treatment modalities for old world cutaneous leishmaniasis: a review. Prague Med Rep 2012; 113(2): 105-18.
30. Nilforooshzadeh MA, Jaffari F, Malekafzali B. Efficacy of combined triple therapy (paramomycin ointment, cryotherapy and intralesional Glucantime) in comparison with intralesional Glucantime for the treatment of acute cutaneous leishmaniasis. Iran J Dermatol 2004; 7: 136-9 [In Persian].
31. Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 2003; 97(5): 493–8.
32. Layegh P, Rajabi O, Jafari MR, Emamgholi Tabar Malekshah P, Moghiman T, Ashraf H, et al. Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res 2011; 2011 doi: 10.2011/656323.
33. Larbi EB, al-Khawajah A, al-Gindan Y, Jain S, Abahusain A, al-Zayer A. A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am J Trop Med Hyg 1995; 52(2):166-8.
34. El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study. J Am Acad Dermatol 1992;27(2):227-31.
35. Asilian A, Davami M. Comparison between the efficacy of photodynamictherapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006; 31: 634–7.
36. Carneiro G, Santos DC, Oliveira MC, Fernandes AP, Ferreira LS, Ramaldes GA, et al. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res 2010; 20(1): 16-23.
37. Asadi, Pardakhti A, Moshafi M, Sharifi I. Preparation and in vivo administration of paromomycin niosomes in balb/c mice. Research in Pharmaceutical Sciences 2012;7(5):S373.
38. Ji B., Perani E.G, Petinom C, N Deli L, Grosset J.H. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob agents Chemother 1994; 38(4): 662-7.
39. Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin 2001; 19(1): 79-86.
40. Wadher S.J, Puranik M.P, Karande N.A, Yeole P.G. Synthesis and biological evaluation of Schiff base of dapsone and their derivative as antimicrobial agents. International Journal of PharmTech Research 2009; 1(1): 22-33.
41. Raeiszadeh M. Preparation and Characterization of Dapsone-Loaded Niosomal Gel for Local Treatment of Cutaneous Leishmaniasis: Kerman, Iran: School of Pharmacy, Kerman University of Medical Sciences; 2012 [updated 26 Nov 2012 18:17; cited PhD 7 april 2014]. 11-9]. Available from: http://eprints.kmu.ac.ir/5252/1/134.pdf.
42. Manconi M., Sinico C, Valenti D, Lai F, Fadda A.M. Niosomes as carriers for tretinoin: III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm 2006; 311(1): 11-9.
43. Fazaeli A, Fouladi B, Sharifi I. Emergence of cutaneous leishmaniasis in a border area at south-east of Iran: an epidemiological survey. J Vector Borne Dis 2009; 46(1): 36-42.